Skip to main content

X-linked Hypophosphatemia clinical trials at UCSF
6 in progress, 0 open to new patients

  • X-linked Hypophosphatemia Disease Monitoring Program

    Sorry, not currently recruiting here

    The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.

    San Francisco, California and other locations

  • Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to evaluate the effect of KRN23 therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).

    San Francisco, California and other locations

  • Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

    Sorry, in progress, not accepting new patients

    UX023-CL203 is a Phase 2b, open-label, long-term extension study. The study will be conducted in adults to assess the safety and pharmacodynamics of KRN23 administered via subcutaneous injections monthly (every 4 weeks) for a total of 68 weeks. The study will enroll approximately 25 adults with XLH who participated in Kyowa Hakko Kirin Pharma, Inc.'s (KHK's) study KRN23-INT-001 or KRN23-INT-002. Subjects will need to discontinue oral phosphate and vitamin D metabolite therapy prior to enrollment and throughout the duration of the study.

    San Francisco, California and other locations

  • Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).

    San Francisco, California and other locations

  • Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

    Sorry, in progress, not accepting new patients

    The primary efficacy objective of this study is to establish the effect of KRN23 treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.

    San Francisco, California and other locations

  • Study of KRN23, a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

    Sorry, in progress, not accepting new patients

    The objectives of the study are to: - Identify a dose and dosing regimen of KRN23, based on safety and pharmacodynamic (PD) effect, in pediatric XLH patients - Establish the safety profile of KRN23 for the treatment of children with XLH including ectopic mineralization risk, cardiovascular effects, and immunogenicity profile - Characterize the pharmacokinetic (PK)/PD profile of the KRN23 doses tested in the monthly (Q4) and biweekly (Q2) dose regimens in pediatric XLH patients - Determine the PD effects of KRN23 treatment on markers of bone health in pediatric XLH patients - Obtain a preliminary assessment of the clinical effects of KRN23 on bone health and deformity, muscle strength, and motor function - Obtain a preliminary assessment of the effects of KRN23 on patient-reported outcomes, including pain, disability, and quality of life in pediatric XLH patients - Evaluate the long-term safety and efficacy of KRN23 Evaluate the long-term safety and efficacy of KRN23

    San Francisco, California and other locations

Last updated: